Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis.

• Tác giả: Emmanuelle Bompas, Ananya Choudhury, Corneel Coens, Felipe Cruz, Karine Martins da Trindade, Gedske Daugaard, Beatrice Fournier, Enrique Gallardo, Silke Gillessen, Frederic Lecouvet, Yohann Loriot, Pablo Maroto, Ray McDermott, Franco Nolè, Manuel Herrero Polo, Daniel D'Almeida Preto, Alejo Rodriguez-Vida, Thierry Roumeguere, Fred Saad, Iwona Skoneczna, Bertrand Tombal, Fabio Turco, Pedro Isaacsson Velho, Rosley Yamamura
• Ngôn ngữ: eng
• Ký hiệu phân loại: 283.3 Branches not in communion with the See of Canterbury
• Thông tin xuất bản: Switzerland : European urology , 2025
• Bộ sưu tập: NCBI
• ID: 217366

Tóm tắt

Bone health is central to the management of patients with metastatic castration-resistant prostate cancer (mCRPC). International guidelines recommend giving a bone-protecting agent (BPA) to patients with mCRPC and bone metastases. However, the data supporting these recommendations were generated before androgen receptor pathway inhibitors (ARPIs) were available. Here we publish for the first time fracture rates from an interim safety analysis of the international prospective phase 3 PEACE-3 trial comparing radium-223 (